Compare Bristol-Myers Squibb Co (BMY) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Docusign Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.57 (market cap $129.94B), while Docusign Inc trades at $58.52 (market cap $11.33B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.5× Docusign Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| BMY | DOCU | |
|---|---|---|
Market Cap | $129.94B | $11.33B |
Sector | Health | Technology |
52-Week High | $65.89 | $85.01 |
52-Week Low | $42.60 | $41.75 |
Enterprise Value | $163.92B | $10.70B |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
